| 07/01/22 | Delisting of AS "Olainfarm” shares from the Baltic Main list | AQ |
| 06/01/22 | Notification about results of final buy-back of shares | AQ |
| 30/12/21 | Notification about final share buy-back | AQ |
| 28/12/21 | Correction: Regarding results of a share buy-back offer | AQ |
| 28/12/21 | On substantial participation (4) - specified | AQ |
| 1 day | -0.24% |
| Manager | Title | Age | Since |
|---|---|---|---|
Juris Hmelnickis
CEO | Chief Executive Officer | 46 | 01/01/2026 |
Janis Leimanis
DFI | Director of Finance/CFO | 56 | - |
| Chief Tech/Sci/R&D Officer | - | 01/01/2010 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 63 | 19/06/2021 | |
Janis Buks
CHM | Chairman | - | 01/09/2022 |
Roberts Tavjevs
BRD | Director/Board Member | - | - |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.24% | -3.46% | - | - | 148M | |
| -0.61% | -3.43% | +36.07% | +115.04% | 1,019B | |
| -1.02% | -5.60% | +35.72% | +64.63% | 617B | |
| +1.11% | -0.58% | +12.36% | +77.95% | 464B | |
| +0.34% | -3.01% | +61.79% | +41.24% | 356B | |
| +0.49% | -2.62% | +20.01% | +40.29% | 333B | |
| +0.87% | -3.39% | +10.85% | +34.45% | 267B | |
| +0.13% | -4.90% | -6.65% | +8.97% | 244B | |
| -1.04% | -2.79% | +35.30% | +51.84% | 218B | |
| -1.87% | -4.10% | +28.44% | +93.66% | 179B | |
| Average | -0.18% | -3.54% | +25.99% | +58.67% | 410.8B | |
| Weighted average by Cap. | -0.20% | -3.54% | +29.01% | +70.56% |
Employees
2,191
Sector
Pharmaceuticals
